Altos Labs vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Altos Labs is a longevity biotech company focused on cellular rejuvenation programming to reverse disease and extend healthspan; raised $3B at launch in 2022 backed by Jeff Bezos and Yuri Milner;
About
Altos Labs is a biotechnology company incorporated in 2021 and publicly launched in January 2022 with an extraordinary $3 billion Series A — the largest biotech launch funding round in history. The company is backed by Jeff Bezos and Yuri Milner, among others, and is headquartered in San Carlos, California, with research institutes in Cambridge, UK, and Japan. Altos Labs is focused on biological reprogramming and cellular rejuvenation — the scientific field exploring whether Yamanaka factors (a set of transcription factors that can reset a cell's epigenetic age) can be applied therapeutically to reverse disease progression and restore cellular function in aging tissues without causing cancer or loss of cell identity.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.